time for the metacarpophalangeal (MCP) joints might yield some disadvantages. Having the hand and arm immobilised for this long might discomfort the patients, thereby reducing acceptability, resulting in poor adherence. The longer imaging time might also increase the risk of motion-induced image degradation.

**Objectives:** The objective of this study was two-fold. Firstly, we investigated motion-induced image degradation of 2nd and 3rd MCP joints for two methods of standardised positioning of the hand. Secondly, the acceptability of HR-pQCT imaging was explored for patients with established Rheumatoid Arthritis (RA).

**Methods:** Fifty patients with RA had their 2nd and 3rd MCP joints imaged by HR-pQCT. The patients were scanned two times, using a custom-made positioning splint, with and without an inflatable immobilisation device. In order to investigate acceptability, the patients were afterwards given a questionnaire regarding their procedure experience of HR-pQCT imaging with and without the inflatable hand immobilisation device. For each acquisition, the image quality was graded, and the number, width, depth and length of cortical interruptions were measured. Twenty percent of the acquisitions were re-evaluated to determine intrarater reliability using the intraclass correlation coefficient (ICC).

**Results:** The acceptability regarding HR-pQCT imaging was high, with only 6% preferring conventional X-ray compared to 40% of the patients preferring HR-pQCT imaging. The remaining 54% were indifferent to the modality. Seventy-four percent found it hard to keep their fingers at rest during the imaging. Fifty percent of the patients thought the inflatable hand immobilisation device helped keep their fingers at rest compared to only 6% who believed it impaired their ability to keep their fingers at rest. This was not observable in the image quality, however, as the overall image quality was high and no clinically relevant difference of the visual grading between the acquisitions with and without the inflatable hand immobilisation device was observed. The number, width, depth and length of cortical interruption all indicated excellent reproducibility as shown in Table 1. No discernible difference between the two acquisitions was observed.

### Table 1. Intraclass correlation coefficients for the number, width, depth and length of cortical interruptions, with and without the inflatable hand immobilization device.

<table>
<thead>
<tr>
<th></th>
<th>Acquisition 1</th>
<th>Acquisition 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cortical interruptions number</td>
<td>0.99 (0.94 to 1.00)</td>
<td>0.98 (0.91 to 1.00)</td>
</tr>
<tr>
<td>Average cortical interruption width</td>
<td>0.98 (0.92 to 0.99)</td>
<td>0.99 (0.95 to 1.00)</td>
</tr>
<tr>
<td>Average cortical interruption depth</td>
<td>0.98 (0.92 to 0.99)</td>
<td>0.97 (0.89 to 0.99)</td>
</tr>
<tr>
<td>Average cortical interruption length</td>
<td>0.93 (0.75 to 0.98)</td>
<td>0.98 (0.94 to 1.00)</td>
</tr>
</tbody>
</table>

Acquisition 1 - Without the inflatable hand immobilization device.
Acquisition 2 - With the inflatable hand immobilization device.

Data presented as mean (95% confidence intervals).

**Conclusion:** The high acceptability signifies the feasibility of the novel HR-pQCT imaging; this was evident by the fact that most patients preferred HR-pQCT imaging compared to conventional X-ray examination. The inflatable hand immobilisation device did not reduce vascular features only. Moreover, the consecutive addition of functional impairment and worsening of ILD from both normal %FVC and %DLco, to %DLco impairment only to both %FVC and %DLco impairment, there was a significant increase in %TV, % AV and %V, with the exception of decrease in %VV and venous density in patients with double impairment versus DLco single impairment.

**Disclosure of Interests:** Rasmus Klose-Jensen: None declared, Krsten Krarup Keller: None declared, Bente Langdahl Grant/research support from: Amgen, NovoNordisk, Catabasis, Argenx Inc., Eli Lilly, UCSB Pharma, Eliken, Margaretse Hauge: None declared.

DOI: 10.1136/annrheumdis-2020-eular.3728

**SAT0545**

### SONOGRAPHIC ASSESSMENT OF CALCIUM PYROPHOSPHATE DEPOSITION DISEASE AT WRIST. A FOCUS ON THE SCAPULO-LUNATE LIGAMENT.

**E. Cipolletta**1, G. Smerilli1, R. Mashadi Mirza2, A. Di Matteo1,3, F. Salaffi1, W. Grassi1, E. Filippucci1,4,5, Università Politecnica delle Marche, Rheumatology Unit, Jesi, Ancona, Italy;6 ULS E Euganea, Dipartimento di Diagnostica per Immagini, Padova, Italy;7 University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom

**Background:** Only few articles evaluated the wrist in calcium pyrophosphate deposition disease (CPPD), although it is the second most frequent target of CPPD. Very recently, in a computed tomography (CT) study ligamentous calcifications were reported as a highly specific feature of CPPD at wrist level.

**Objectives:** i) to determine the prevalence and distribution of the ultrasound (US) findings indicative of calcium pyrophosphate (CPP) crystal deposits at the wrist, with a particular focus on the dorsal aspect of the scapho-lunate ligament (SLL); ii) to investigate the diagnostic accuracy of US and conventional radiography (CR) in the evaluation of CPP crystal deposits at wrist level, iv) to assess the agreement between the different imaging techniques.

**Methods:** Consecutive patients with a “definite” diagnosis of CPPD according to the 2010 and 2015 criteria were consecutively included in two cross-sectional single-centre study. Dorsal part of the SLL, triangular fibrocartilage complex (TFCC), and volar recess of the radiocarpal-lunate joint were examined using US (according to EULAR standard scans and OMERACT definitions), CR and CT.

**Results:** Sixty-one CPPD patients and 39 disease controls were enrolled. Two-hundred wrists were evaluated using both CR and US. CT data of 26 (13.0%) showed CPPD at one and 6 wrists in controls. CPP crystal deposits were found by US in at least one wrist in 95.1% of CPPD patients and in 15.4% of controls (p<0.001). SLL calcification was reported in 83.6% of CPPD patients and in 5.1% of controls (p<0.001). CPP crystal deposits were...
observed by US at the SLL and/or radio-lunate joint in 5.7% of wrists and 6.6% of CPPD patients, but not at the TFCC of the same wrist. On CR, calcifications were found in at least one wrist in 72.1% of CPPD patients and in 0% of controls (p<0.001). Using the Ryan-McCarty criteria as a gold standard, the sensitivity, specificity and diagnostic accuracy were 0.72 (0.59-0.83), 1.0 (0.91-1.0) and 0.83 (0.74-0.90) for CR and 0.95 (0.86-0.99), 0.85 (0.69-0.94) and 0.91 (0.84-0.96) for US. Table 1 shows the agreement between the different imaging techniques.

Table 1. Agreement between US and the other imaging techniques in the evaluation of CPP crystal deposits at the wrist.

<table>
<thead>
<tr>
<th>Imaging Technique</th>
<th>US-CR (n=200)</th>
<th>US-CT (n=26)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TFCC</td>
<td>0.65 (0.43-0.87)</td>
<td>0.72 (0.43-0.97)</td>
</tr>
<tr>
<td>SLL</td>
<td>0.23 (0.07-0.39)</td>
<td>0.69 (0.41-0.97)</td>
</tr>
<tr>
<td>RLJ</td>
<td>0.25 (0.09-0.41)</td>
<td>0.46 (0.12-0.80)</td>
</tr>
</tbody>
</table>

Legend: n: number of the wrists, RLJ: volar recess of the radio-lunate joint. Values in brackets are the 95% confidence intervals of the Cohen’s kappa.

Conclusion: This study supports the diagnostic accuracy of US in evaluating wrist involvement in CPPD patients. SLL calcifications are a specific US finding of CPPD at wrist level.

References:

Disclosure of Interests: Edoardo Cipolletta: None declared, Gianluca Smerilli: None declared, Riccardo Mashadi Mirza: None declared, Andrea Di Matteo: None declared,报价 Grant/research support from: Pfizer, Con- sultant of: Novartis, Gilead, Lilly, Sanofi, Celgene, Speakers bureau: Lilly, Cristina Garu: None declared, Maria Della Cotta: None declared, Francesca Romana Spinelli Grant/research support from: Pfizer, Consultant of: Novartis, Gilead, Lilly, Sanofi, Celgene, Speakers bureau: Lilly, Cristina Di Franco: None declared, Roberta Priori: None declared, Valeria Riccieri: None declared, Silvia Mancuso: None declared, Elena Garufi: None declared, Ilaria Duca: None declared, Francesca Romana Spinelli: None declared, Cristina Di Franco: None declared, Elena Garufi: None declared, Ilaria Duca: None declared, Silvia Mancuso: None declared.

Background: Therapeutic approach of rheumatoid arthritis (RA) patients has been enriched by the introduction of small molecules. In particular Jak inhibitors (JAKi), baricitinib and tofacitinib, demonstrated their efficacy in patients naïve or resistant to biological treatments in randomized controlled trials. Moreover, these drugs seem to be able to prevent radiographic progression. To date few data are available from the real life context. Ultrasonographic (US) assessment has become a valid imaging tool in the management of RA patients in clinical practice, allowing the evaluation of joint inflammatory status. Together with clinimetric assessment, US could provide a comprehensive assessment of drug response.

Methods: In the present study we aimed at assessing the early response to JAKi treatment by using musculoskeletal US.

Results: In the present study, specifically designed to evaluate the US-detected efficacy of JAKi in RA patients, we demonstrated in a real life setting a significant, early and sustained improvement of inflammatory joint status. The median CRP value at the US visit was 22 (IQR 11). No significant differences were found when subgrouping patients according to different JAKi drug, in terms US and clinimetric assessment.

Conclusion: In this prospective longitudinal study, we collected data about all consecutive active RA patients starting treatment with JAKi. RA was diagnosed according to the 2010 ACR/EULAR criteria. At each visit, clinical and laboratory data were collected in a standardized and computerized form, including demographics, past medical history, co-morbidities, previous and concomitant treatments. According with study protocol, all patients underwent clinical and US assessment at the following time-points: baseline (T0), 4 weeks (T1) and 12 weeks (T2). Clinical evaluation included tender and swollen joint counts (0-28), patients global health assessment. C-reactive protein (CRP) levels were registered and disease activity was calculated by disease activity score (DAS) in 28 joints by using CRP (DAS28-CRP). A systematic multianalysys grey-scale and power Doppler (pD) US examination was performed by using MyLab Eight Expert Machine (Esaote, Florence, Italy) at level of 22 joints (bilateral I-V metacarpophalangeal, I-V proximal interphalangeal, wrist). According with OMERACT definitions we assessed the presence of synovial effusion, hypertrophy and pD, that were scored according to a semi-quantitative scale (0-3). A total US inflammatory score (0-186) was obtained by their sum.

Results: We enrolled 91 patients [F/M 77/14; median age 60.0 years (IQR 15.5); median disease duration 144 months (IQR 126)]. Of these patients, 54 (59.3%) were treated by baricitinib and the remaining 37 by tofacitinib. At baseline we found a median US inflammatory score of 20 (IQR 18.7) and a median DAS28-CRP of 5.0 (IQR 1.56). US assessment demonstrated significant reduction in the median values of inflammatory score already at T1 (median 13 (IQR 14.7), p<0.0001), that was maintained at T2 (median 10 (IQR 11), p<0.0001). These results are represented in figure 1. Similar to US inflammatory score, a significant reduction was registered for DAS28-CRP median values [T1 3.5 (IQR 1.73), p<0.0001; T2 3.3 (IQR 1.8), p<0.0001]. No significant differences were found when subgrouping patients according to different JAKi drug, in terms US and clinimetric assessment.

Conclusion: In this prospective longitudinal study, we collected data about all consecutive active RA patients starting treatment with JAKi. RA was diagnosed according to the 2010 ACR/EULAR criteria. At each visit, clinical and laboratory data were collected in a standardized and computerized form, including demographics, past medical history, co-morbidities, previous and concomitant treatments. According with study protocol, all patients underwent clinical and US assessment at the following time-points: baseline (T0), 4 weeks (T1) and 12 weeks (T2). Clinical evaluation included tender and swollen joint counts (0-28), patients global health assessment. C-reactive protein (CRP) levels were registered and disease activity was calculated by disease activity score (DAS) in 28 joints by using CRP (DAS28-CRP). A systematic multianalysys grey-scale and power Doppler (pD) US examination was performed by using MyLab Eight Expert Machine (Esaote, Florence, Italy) at level of 22 joints (bilateral I-V metacarpophalangeal, I-V proximal interphalangeal, wrist). According with OMERACT definitions we assessed the presence of synovial effusion, hypertrophy and pD, that were scored according to a semi-quantitative scale (0-3). A total US inflammatory score (0-186) was obtained by their sum.

Results: We enrolled 91 patients [F/M 77/14; median age 60.0 years (IQR 15.5); median disease duration 144 months (IQR 126)]. Of these patients, 54 (59.3%) were treated by baricitinib and the remaining 37 by tofacitinib. At baseline we found a median US inflammatory score of 20 (IQR 18.7) and a median DAS28-CRP of 5.0 (IQR 1.56). US assessment demonstrated significant reduction in the median values of inflammatory score already at T1 (median 13 (IQR 14.7), p<0.0001), that was maintained at T2 (median 10 (IQR 11), p<0.0001). These results are represented in figure 1. Similar to US inflammatory score, a significant reduction was registered for DAS28-CRP median values [T1 3.5 (IQR 1.73), p<0.0001; T2 3.3 (IQR 1.8), p<0.0001]. No significant differences were found when subgrouping patients according to different JAKi drug, in terms US and clinimetric assessment.

Conclusion: In this present study, specifically designed to evaluate the US-detected efficacy of JAKi in RA patients, we demonstrated in a real life setting a significant, early and sustained improvement of inflammatory joint status.

Figure 1. Box and whiskers plot (median, quartiles, range) of US inflammatory score of 91 RA patients at baseline (T0), after 4 weeks (T1) and 12 weeks (T2) of treatment with JAKi. P values were referred to the comparison with baseline.

References:

Disclosure of Interests: enrica cipriano: None declared, Fulvia Ceccarelli: None declared, Francesca Romana Spinelli Grant/research support from: Pfizer, Consultant of: Novartis, Gilead, Lilly, Sanofi, Celgene, Speakers bureau: Lilly, Cristina Garufi: None declared, Maria Della Cotta: None declared, Cristina Di Franco: None declared, Roberta Priori: None declared, Valeria Riccieri: None declared.